JP2016534048A5 - - Google Patents

Download PDF

Info

Publication number
JP2016534048A5
JP2016534048A5 JP2016522040A JP2016522040A JP2016534048A5 JP 2016534048 A5 JP2016534048 A5 JP 2016534048A5 JP 2016522040 A JP2016522040 A JP 2016522040A JP 2016522040 A JP2016522040 A JP 2016522040A JP 2016534048 A5 JP2016534048 A5 JP 2016534048A5
Authority
JP
Japan
Prior art keywords
cancer
compound according
aryl
alkyl
compound
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2016522040A
Other languages
English (en)
Japanese (ja)
Other versions
JP6765302B2 (ja
JP2016534048A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/CA2014/050974 external-priority patent/WO2015051458A1/en
Publication of JP2016534048A publication Critical patent/JP2016534048A/ja
Publication of JP2016534048A5 publication Critical patent/JP2016534048A5/ja
Application granted granted Critical
Publication of JP6765302B2 publication Critical patent/JP6765302B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2016522040A 2013-10-08 2014-10-08 標的化化学療法に使用するための非白金ベースの抗がん化合物 Expired - Fee Related JP6765302B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201361887988P 2013-10-08 2013-10-08
US61/887,988 2013-10-08
PCT/CA2014/050974 WO2015051458A1 (en) 2013-10-08 2014-10-08 Non-platimun-based anti-cancer compounds for use in targeted chemotherapy

Publications (3)

Publication Number Publication Date
JP2016534048A JP2016534048A (ja) 2016-11-04
JP2016534048A5 true JP2016534048A5 (enExample) 2018-02-15
JP6765302B2 JP6765302B2 (ja) 2020-10-07

Family

ID=52812401

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2016522040A Expired - Fee Related JP6765302B2 (ja) 2013-10-08 2014-10-08 標的化化学療法に使用するための非白金ベースの抗がん化合物

Country Status (8)

Country Link
US (2) US10463662B2 (enExample)
EP (2) EP3055287B1 (enExample)
JP (1) JP6765302B2 (enExample)
KR (1) KR102307387B1 (enExample)
CN (2) CN114380700A (enExample)
AU (1) AU2014334461B2 (enExample)
CA (1) CA2926571C (enExample)
WO (1) WO2015051458A1 (enExample)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2899906T3 (es) 2015-07-06 2022-03-15 Alkermes Inc Inhibidores bicíclicos de histona desacetilasa
EP3319968A1 (en) 2015-07-06 2018-05-16 Rodin Therapeutics, Inc. Heterobicyclic n-aminophenyl-amides as inhibitors of histone deacetylase
EA202092442A3 (ru) 2016-06-07 2021-08-31 Джакобио Фармасьютикалс Ко., Лтд. Новые гетероциклические производные, применимые в качестве ингибиторов shp2
US11168068B2 (en) 2016-07-18 2021-11-09 Janssen Pharmaceutica Nv Tau PET imaging ligands
ES2875562T3 (es) 2017-01-11 2021-11-10 Alkermes Inc Inhibidores bicíclicos de histona desacetilasa
KR102317480B1 (ko) 2017-03-23 2021-10-25 자코바이오 파마슈티칼스 컴퍼니 리미티드 Shp2 억제제로서 유용한 신규한 헤테로환형 유도체
US11225475B2 (en) 2017-08-07 2022-01-18 Alkermes, Inc. Substituted pyridines as inhibitors of histone deacetylase
WO2020063760A1 (en) 2018-09-26 2020-04-02 Jacobio Pharmaceuticals Co., Ltd. Novel heterocyclic derivatives useful as shp2 inhibitors

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3822261A (en) * 1972-10-30 1974-07-02 Dow Chemical Co 5,6-dihalo-2-fluoroalkyl-1h-imidazo(4,5-b)pyrazines
EP0743855A1 (en) * 1994-01-03 1996-11-27 Acea Pharmaceuticals, Inc. 8-aza, 6-aza and 6,8-diaza-1,4-dihydroquinoxaline-2,3-diones and the use thereof as antagonists for the glycine/nmda receptor
US7622117B2 (en) 2002-04-17 2009-11-24 Dynamis Therapeutics, Inc. 3-deoxyglucosone and skin
DE102004054545A1 (de) * 2004-09-16 2006-04-06 Max-Delbrück-Centrum für Molekulare Medizin Änderung des Beladungszustandes von MHC-Molekülen
US20060089316A1 (en) * 2004-10-25 2006-04-27 Brown Truman R Method for reducing a susceptibility to tumor formation induced by 3-deoxyglucosone and precursors thereof
GB0428082D0 (en) 2004-12-22 2005-01-26 Welcome Trust The Ltd Therapeutic compounds
CN101203509B (zh) * 2005-02-16 2013-05-08 默沙东公司 具有cxcr3拮抗剂活性的胺-连接的吡啶基和苯基取代的哌嗪-哌啶
JP5178738B2 (ja) 2006-12-20 2013-04-10 メルク・シャープ・アンド・ドーム・コーポレーション 新規なｊｎｋ阻害剤
CN103450077B (zh) * 2007-06-08 2016-07-06 满康德股份有限公司 IRE-1α抑制剂
JP2010536723A (ja) * 2007-08-16 2010-12-02 エフ．ホフマン−ラ ロシュ アーゲー 置換ヒダントイン
DK200801600A (en) * 2008-11-17 2010-05-18 Engkilde Kaare Method for treatment of inflammatory diseases
US8722720B2 (en) * 2009-10-28 2014-05-13 Newlink Genetics Corporation Imidazole derivatives as IDO inhibitors
WO2012096813A1 (en) * 2011-01-11 2012-07-19 Merck Sharp & Dohme Corp. Imidazole derivatives
MX2015008010A (es) 2012-12-20 2016-04-26 qing-bin Lu Compuestos radiosensabilizadores para usarse en combinacion con radiacion.

Similar Documents

Publication Publication Date Title
JP2016534048A5 (enExample)
JP2019514863A5 (enExample)
MX2020005363A (es) Compuestos heterociclicos como inhibidores de prmt5.
JP2016504325A5 (enExample)
JP2019529500A5 (enExample)
JP2019535720A5 (enExample)
JP2010539095A5 (enExample)
JP2017509586A5 (enExample)
WO2016160617A3 (en) Inhibitors of cyclin-dependent kinases
JP2019518766A5 (enExample)
JP2020506951A5 (enExample)
JP2009534408A5 (enExample)
WO2016105528A3 (en) Inhibitors of cyclin-dependent kinase 7 (cdk7)
JP2015512943A5 (enExample)
JP2008535902A5 (enExample)
JP2020510091A5 (enExample)
JP2016513137A5 (enExample)
JP2016518328A5 (enExample)
JP2017528502A5 (enExample)
WO2017044858A3 (en) Inhibitors of cyclin-dependent kinases
JP2014501766A5 (enExample)
TR201809990T4 (en) NEW COMPOSITIONS, USES AND METHODS FOR THEIR MAKING.
JP2016505010A5 (enExample)
JP2016537382A5 (enExample)
JP2016539985A5 (enExample)